Showing 641-660 of 8875 for: Cochrane Systematic Reviews Back
- Antidepressants for treating depression in dementia
Cochrane Systematic Reviews, 31-Aug-2018
The use of antidepressants in dementia accompanied by depressive symptoms is widespread, but their clinical efficacy is uncertain. This review updates an earlier version, first published in 2002.
- Antidepressants plus benzodiazepines for adults with major depression
Cochrane Systematic Reviews, 3-Jun-2019
Anxiety frequently coexists with depression and adding benzodiazepines to antidepressant treatment is common practice to treat people with major depression. However, more evidence is needed to determine whether this combined treatment is more effective an
- Antidepressants versus placebo for depression in primary care
Cochrane Systematic Reviews, 8-Jul-2009
Concern has been expressed about the relevance of secondary care studies to primary care patients specifically about the effectiveness of antidepressant medication. There is a need to review the evidence of only those studies that have been conducted comp
- Antidepressants versus placebo for panic disorder in adults
Cochrane Systematic Reviews, 5-Apr-2018
Panic disorder is characterised by repeated, unexpected panic attacks, which represent a discrete period of fear or anxiety that has a rapid onset, reaches a peak within 10 minutes, and in which at least four of 13 characteristic symptoms are experienced,
- Antidepressants versus placebo for people with bulimia nervosa
Cochrane Systematic Reviews, 20-Oct-2003
Bulimia Nervosa (BN) represents an important public health problem and is related to serious morbidity and even mortality. This review attempted to systematically evaluate the use of antidepressant medications compared with placebo for the treatment of bu
- Antidepressants versus placebo for the depressed elderly
Cochrane Systematic Reviews, 22-Jan-2001
Depression warranting intervention is found in ten percent of people over the age of 60. Older depressed people are more likely to die than non-depressed. Relatively few receive therapeutic interventions, and those that do, tend to receive low dose antide
- Antidepressants versus psychological treatments and their combination for bulimia nervosa
Cochrane Systematic Reviews, 23-Oct-2001
Psychotherapeutic approaches, mainly cognitive behavior therapy, and antidepressant medication are the two treatment modalities that have received most support in controlled outcome studies of bulimia nervosa.
- Antidotes for acute cardenolide (cardiac glycoside) poisoning
Cochrane Systematic Reviews, 18-Oct-2006
Cardenolides are naturally occurring plant toxins which act primarily on the heart. While poisoning with the digitalis cardenolides (digoxin and digitoxin) are reported worldwide, cardiotoxicity from other cardenolides such as the yellow oleander are also
- Antiemetic medication for prevention and treatment of chemotherapy‐induced nausea and vomiting in childhood
Cochrane Systematic Reviews, 2-Feb-2016
Nausea and vomiting remain a problem for children undergoing treatment for malignancies despite new antiemetic therapies. Optimising antiemetic regimens could improve quality of life by reducing nausea, vomiting, and associated clinical problems. This is
- Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
Cochrane Systematic Reviews, 16-Nov-2021
About 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy. Combining 5-hyd
- Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents
Cochrane Systematic Reviews, 7-Aug-2011
Vomiting is a common manifestation of acute gastroenteritis in children and adolescents. When untreated it can be a hindrance to oral rehydration therapy, which is the cornerstone in the management of acute gastroenteritis. Evidence is needed concerning t
- Anti‐epidermal growth factor receptor therapy for glioblastoma in adults
Cochrane Systematic Reviews, 12-May-2020
Glioblastoma is an uncommon but highly aggressive type of brain tumour. Significant gains have been achieved in the molecular understanding and the pathogenesis of glioblastomas, however clinical improvements are difficult to obtain for many reasons. The
- Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data
Cochrane Systematic Reviews, 1-Apr-2022
This is an updated version of the original Cochrane Review published in 2017.
- Antiepileptic drugs as prophylaxis for postcraniotomy seizures
Cochrane Systematic Reviews, 28-Apr-2020
This is an updated version of the Cochrane Review previously published in 2018.
- Antiepileptic drugs for chronic non‐cancer pain in children and adolescents
Cochrane Systematic Reviews, 5-Aug-2017
Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health Organization (WHO) guidelines for pharmacological treatments for children's persisting pain acknowledge that pain in
- Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews
Cochrane Systematic Reviews, 11-Nov-2013
Antiepileptic drugs have been used for treating different types of neuropathic pain, and sometimes fibromyalgia. Our understanding of quality standards in chronic pain trials has improved to include new sources of potential bias. Individual Cochrane revie
- Antiepileptic drugs for preventing seizures following acute traumatic brain injury
Cochrane Systematic Reviews, 16-May-2012
Seizure activity in the early post-traumatic period following head injury may cause secondary brain damage as a result of increased metabolic demands, raised intracranial pressure and excess neurotransmitter release.
- Antiepileptic drugs for preventing seizures in people with brain tumors
Cochrane Systematic Reviews, 19-Oct-2008
Seizures can present at any time before or after diagnosis of a brain tumor. The risk of seizures varies by tumor type and its location in the brain. For a long time we believed that preventing seizures with antiepileptic drugs (seizure prophylaxis) was e
- Antiepileptic drugs for seizure control in people with neurocysticercosis
Cochrane Systematic Reviews, 1-Nov-2021
Neurocysticercosis is the most common parasitic infection of the brain. Epilepsy is the most common clinical presentation, though people may also present with headache, symptoms of raised intracranial pressure, hydrocephalus, and ocular symptoms depending
- Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis
Cochrane Systematic Reviews, 21-Apr-2016
Intracranial venous thrombosis (ICVT) commonly presents with seizures in the acute period, and some people may develop recurrent seizures in the long term. The prophylactic use of antiepileptic drugs (AEDs) for the management of post-ICVT seizures is cont
